Short- and long-term mortality in patients with type 2 diabetes after myocardial infarction- a nationwide registry study.
Mortality
Myocardial infarction
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
29
08
2024
accepted:
20
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has intensified. We evaluated the short- and long-term mortality rates of patients with type 2 diabetes after MI and explored the associations between the characteristics of patients with type 2 diabetes and MI mortality. Mortality rates among consecutive MI patients with type 2 diabetes using oral antidiabetic medication (n = 13,152; 40% female; mean age 73.6 years) and MI patients without diabetes (n = 77,669) treated in Finland from 2004 to 2018 were retrospectively studied using a combination of national registries (median follow-up 5.7 years). Differences between groups were balanced with multivariable adjustments and propensity score matching. Mortality was higher in patients with type 2 diabetes than in the propensity score-matched controls without diabetes at 30 days (12.6% versus 12.0%: p = 0.013), at 1 year (22.4% versus 21.4%; p = 0.001), and at 15 years (83.2% vs. 73.4%; HR 1.20; 95% CI 1.17-1.24; p < 0.0001) after MI. In subgroup analyses, type 2 diabetes was associated with a poorer prognosis across the spectrum of MI patients. The excess mortality risk was attenuated by increasing age but was similar in both sexes. Male sex, age, cardiovascular and noncardiovascular co-morbidities, lack of revascularization, a longer duration of diabetes, and baseline insulin therapy were associated with increased mortality in patients with type 2 diabetes. The one-year prognosis of patients with type 2 diabetes improved during the study period, but the mortality gap compared to patients without diabetes was not altered. Type 2 diabetes had a negative impact on both short- and long-term outcome after MI, but effect sizes were relatively small. Patients with longer duration of diabetes or need for insulin therapy are still at particular risk.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has intensified. We evaluated the short- and long-term mortality rates of patients with type 2 diabetes after MI and explored the associations between the characteristics of patients with type 2 diabetes and MI mortality.
METHODS
METHODS
Mortality rates among consecutive MI patients with type 2 diabetes using oral antidiabetic medication (n = 13,152; 40% female; mean age 73.6 years) and MI patients without diabetes (n = 77,669) treated in Finland from 2004 to 2018 were retrospectively studied using a combination of national registries (median follow-up 5.7 years). Differences between groups were balanced with multivariable adjustments and propensity score matching.
RESULTS
RESULTS
Mortality was higher in patients with type 2 diabetes than in the propensity score-matched controls without diabetes at 30 days (12.6% versus 12.0%: p = 0.013), at 1 year (22.4% versus 21.4%; p = 0.001), and at 15 years (83.2% vs. 73.4%; HR 1.20; 95% CI 1.17-1.24; p < 0.0001) after MI. In subgroup analyses, type 2 diabetes was associated with a poorer prognosis across the spectrum of MI patients. The excess mortality risk was attenuated by increasing age but was similar in both sexes. Male sex, age, cardiovascular and noncardiovascular co-morbidities, lack of revascularization, a longer duration of diabetes, and baseline insulin therapy were associated with increased mortality in patients with type 2 diabetes. The one-year prognosis of patients with type 2 diabetes improved during the study period, but the mortality gap compared to patients without diabetes was not altered.
CONCLUSIONS
CONCLUSIONS
Type 2 diabetes had a negative impact on both short- and long-term outcome after MI, but effect sizes were relatively small. Patients with longer duration of diabetes or need for insulin therapy are still at particular risk.
Identifiants
pubmed: 39478565
doi: 10.1186/s12933-024-02479-6
pii: 10.1186/s12933-024-02479-6
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
390Informations de copyright
© 2024. The Author(s).
Références
Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13.
pubmed: 25466521
pmcid: 4303913
doi: 10.1016/S2213-8587(14)70219-0
Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 1997;20(5):704–8.
pubmed: 9135930
doi: 10.2337/diacare.20.5.704
Gustafsson I, Hildebrandt P, Seibaek M, et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J. 2000;21(23):1937–43.
pubmed: 11071799
doi: 10.1053/euhj.2000.2244
Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction Register Study Group. Diabetes Care. 1998;21(1):69–75.
pubmed: 9538972
doi: 10.2337/diacare.21.1.69
Alabas OA, Hall M, Dondo TB, et al. Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study. J Epidemiol Community Health. 2017;71(1):25–32.
pubmed: 27307468
doi: 10.1136/jech-2016-207402
Eliasson M, Jansson JH, Lundblad D, Näslund U. The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study. Diabetologia. 2011;54(10):2538–43.
pubmed: 21779872
doi: 10.1007/s00125-011-2247-9
Winell KM, Pääkkönen R, Pietilä A, Niemi MK, Reunanen AR, Salomaa VV. Case fatality rates after first acute coronary syndrome in persons treated for type 2 diabetes show an improving trend. Diabetologia. 2010;53(3):472–80.
pubmed: 19997900
doi: 10.1007/s00125-009-1606-2
Ahmed B, Davis HT, Laskey WK. In-hospital mortality among patients with type 2 diabetes mellitus and acute myocardial infarction: results from the national inpatient sample, 2000–2010. J Am Heart Assoc 2014;3(4).
Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke statistics: a report of US and Global Data from the American Heart Association. Circulation. 2024;149(8):e347–913.
pubmed: 38264914
doi: 10.1161/CIR.0000000000001209
American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78.
doi: 10.2337/dc24-S009
American Diabetes Association Professional Practice C. 7. Diabetes Technology: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S126–S144.
American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179–218.
doi: 10.2337/dc24-S010
Kerola AM, Palomäki A, Rautava P, Kytö V. Less revascularization in young women but impaired long-term outcomes in young men after myocardial infarction. Eur J Prev Cardiol. 2022;29(10):1437–45.
pubmed: 35253860
doi: 10.1093/eurjpc/zwac049
Prami T, Khanfir H, Deleskog A, et al. Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. BMJ Open. 2016;6(11):e012604.
pubmed: 27881527
pmcid: 5129076
doi: 10.1136/bmjopen-2016-012604
Kerola AM, Juonala M, Palomäki A, Semb AG, Rautava P, Kytö V. Case fatality of patients with type 1 diabetes after myocardial infarction. Diabetes Care. 2022;45(7):1657–65.
pubmed: 35679070
pmcid: 9274223
doi: 10.2337/dc22-0042
Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12(2):132–7.
pubmed: 15785298
Palomäki A, Kerola AM, Malmberg M, Rautava P, Kytö V. Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study. Rheumatology (Oxford). 2021;60(11):5205–15.
pubmed: 33667301
doi: 10.1093/rheumatology/keab204
Kerola AM, Semb AG, Juonala M, Palomäki A, Rautava P, Kytö V. Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction. Cardiovasc Diabetol. 2022;21(1):177.
pubmed: 36068573
pmcid: 9450422
doi: 10.1186/s12933-022-01608-3
Kytö V, Sipilä J, Ahtela E, Rautava P, Gunn J. Mechanical Versus Biologic prostheses for Surgical aortic valve replacement in patients aged 50 to 70. Ann Thorac Surg. 2020;110(1):102–10.
pubmed: 31786289
doi: 10.1016/j.athoracsur.2019.10.027
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167(4):268–74.
pubmed: 28693043
doi: 10.7326/M16-2607
Koek HL, Soedamah-Muthu SS, Kardaun JW, et al. Short- and long-term mortality after acute myocardial infarction: comparison of patients with and without diabetes mellitus. Eur J Epidemiol. 2007;22(12):883–8.
pubmed: 17926133
pmcid: 2190782
doi: 10.1007/s10654-007-9191-5
Löwel H, Köenig W, Engel S, Hormann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia. 2000;43(2):218–26.
pubmed: 10753044
doi: 10.1007/s001250050032
Norhammar A, Lindbäck J, Ryden L, et al. Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart. 2007;93(12):1577–83.
pubmed: 17237125
pmcid: 2095772
doi: 10.1136/hrt.2006.097956
Nedkoff L, Knuiman M, Hung J, Briffa TG. Improving 30-day case fatality after incident myocardial infarction in people with diabetes between 1998 and 2010. Heart. 2015;101(16):1318–24.
pubmed: 26076939
doi: 10.1136/heartjnl-2015-307627
Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and long-term mortality after myocardial infarction in patients with and without diabetes: changes from 1985 to 2008. Diabetes Care. 2012;35(10):2043–7.
pubmed: 22815296
pmcid: 3447836
doi: 10.2337/dc11-2462
Patel PA, Cubbon RM, Sapsford RJ, et al. An evaluation of 20 year survival in patients with diabetes mellitus and acute myocardial infarction. Int J Cardiol. 2016;203:141–4.
pubmed: 26512829
doi: 10.1016/j.ijcard.2015.10.094
Gruppetta M, Calleja N, Fava S. Long-term survival after acute myocardial infarction and relation to type 2 diabetes and other risk factors. Clin Cardiol. 2010;33(7):424–9.
pubmed: 20641120
pmcid: 6653194
doi: 10.1002/clc.20776
Matetic A, Doolub G, Bharadwaj A, et al. Differential Impact of Type 1 and type 2 diabetes Mellitus on outcomes among 1.4 million US patients undergoing percutaneous coronary intervention. Cardiovasc Revasc Med. 2022;38:83–8.
pubmed: 34446373
doi: 10.1016/j.carrev.2021.08.018
Fojt A, Kowalik R, Gierlotka M, Gasior M, Smeding C, Opolski G. Three-year mortality after acute myocardial infarction in patients with different diabetic status. Pol Arch Intern Med 2021;131(11).
Baviera M, Genovese S, Colacioppo P, et al. Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2022;21(1):223.
pubmed: 36309742
pmcid: 9618227
doi: 10.1186/s12933-022-01655-w
Nedkoff L, Knuiman M, Hung J, Briffa TG. Long-term all-cause and cardiovascular mortality following incident myocardial infarction in men and women with and without diabetes: temporal trends from 1998 to 2009. Eur J Prev Cardiol. 2016;23(12):1273–81.
pubmed: 26907793
doi: 10.1177/2047487316634279
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.
pubmed: 37622654
doi: 10.1093/eurheartj/ehad191
Roger VL, Weston SA, Gerber Y, et al. Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation. 2010;121(7):863–9.
pubmed: 20142444
pmcid: 2827641
doi: 10.1161/CIRCULATIONAHA.109.897249
Marenzi G, Cosentino N, Genovese S, et al. Reduced cardio-renal function accounts for most of the In-Hospital morbidity and mortality risk among patients with type 2 diabetes undergoing primary percutaneous coronary intervention for ST-Segment Elevation myocardial infarction. Diabetes Care. 2019;42(7):1305–11.
pubmed: 31048409
doi: 10.2337/dc19-0047
Brener SJ, Mehran R, Dressler O, Cristea E, Stone GW. Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). Am J Cardiol. 2012;109(8):1111–6.
pubmed: 22244381
doi: 10.1016/j.amjcard.2011.11.046
Giustino G, Colantonio LD, Brown TM, et al. Titration to high-intensity statin therapy following Acute myocardial infarction in patients with and without diabetes Mellitus. Cardiovasc Drugs Ther. 2018;32(5):453–61.
pubmed: 30078077
doi: 10.1007/s10557-018-6816-8
Wikström K, Lamidi ML, Rautiainen P, Tirkkonen H, Laatikainen T. Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013–2019. Diabet Med. 2022;39(9):e14866.
pubmed: 35506179
pmcid: 9543455
doi: 10.1111/dme.14866
Kytö V, Nuotio M, Rautava P. Sex difference in the Case Fatality of older myocardial infarction patients. J Gerontol Biol Sci Med Sci. 2022;77(3):614–20.
doi: 10.1093/gerona/glab152
Lopez-de-Andres A, Jimenez-Garcia R, Hernandez-Barrera V, et al. Are there sex differences in the effect of type 2 diabetes in the incidence and outcomes of myocardial infarction? A matched-pair analysis using hospital discharge data. Cardiovasc Diabetol. 2021;20(1):81.
pubmed: 33888124
pmcid: 8063379
doi: 10.1186/s12933-021-01273-y
Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016;4(2):115–24.
pubmed: 26704379
doi: 10.1016/S2213-8587(15)00508-2
Yaliqin N, Yu ZX, Aimaier S, Adi D, Ma YT. Impact of Duration of Diabetes Mellitus on Long-term outcome in type 2 Diabetic patients with primary percutaneous coronary intervention after the first myocardial infarction. Cardiology 2024.
Hoebers LP, Claessen BE, Woudstra P, et al. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention. 2014;10(1):90–6.
pubmed: 24832639
doi: 10.4244/EIJV10I1A15
Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993;22(7):1788–94.
pubmed: 8245329
doi: 10.1016/0735-1097(93)90758-S
Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135.
pubmed: 26446829
pmcid: 4597459
doi: 10.1186/s12933-015-0300-6
Li Y, Li X, Zhang Y, et al. Impact of glycemic control status on patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2020;20(1):36.
pubmed: 32000678
pmcid: 6993353
doi: 10.1186/s12872-020-01339-x
Sharma PK, Agarwal S, Ellis SG, et al. Association of glycemic control with mortality in patients with diabetes mellitus undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;7(4):503–9.
pubmed: 25097197
doi: 10.1161/CIRCINTERVENTIONS.113.001107